Polaryx Therapeutics (PLYX) FDA Approvals

Polaryx Therapeutics' Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Polaryx Therapeutics (PLYX). Over the past two years, Polaryx Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as PLX-200. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

PLX-200 FDA Regulatory Events

PLX-200 is a drug developed by Polaryx Therapeutics for the following indication: For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Designation Grant - April 21,2026

Fast Track

• Drug: PLX-200
• Announced Date: April 21, 2026
• Indication: For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis

Polaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II).

Polaryx Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II). These are rare, serious genetic disorders that cause progressive neurodegeneration in children. PLX-200 is being developed to address the underlying disease processes, and these FTD decisions apply to its study in the company’s planned SOTERIA Phase 2 basket trial covering these indications.

The Fast Track program is intended to speed development and review of drugs for serious conditions with unmet medical need. Companies with FTD often get more frequent contact with the FDA and may be eligible for rolling review of a future marketing application. Those features can help shorten development timelines and potentially bring treatments to patients sooner.Read Announcement

Designation Grant - March 17,2026

Fast Track

• Drug: PLX-200
• Announced Date: March 17, 2026
• Indication: For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis

Polaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease).

Polaryx Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease). Fast Track is meant to help speed the development and review of drugs for serious conditions with unmet medical needs. The designation can allow more frequent communication with the FDA and may enable a rolling review of a future marketing application, which could shorten the time to reach patients if trials are successful.

This regulatory milestone supports Polaryx’s SOTERIA Phase 2 basket trial, an open-label, single-arm study testing PLX-200’s safety, tolerability, and clinical activity across four rare lysosomal storage disorders: CLN2, CLN3, Krabbe disease, and Sandhoff disease. The Fast Track status may help advance the program as the company continues clinical development.

Polaryx Therapeutics FDA Events - Frequently Asked Questions

Has Polaryx Therapeutics received FDA approval?

As of now, Polaryx Therapeutics (PLYX) has not received any FDA approvals for its therapy in the last two years.

What drugs has Polaryx Therapeutics submitted to the FDA?

In the past two years, Polaryx Therapeutics (PLYX) has reported FDA regulatory activity for PLX-200.

What is the most recent FDA event for Polaryx Therapeutics?

The most recent FDA-related event for Polaryx Therapeutics occurred on April 21, 2026, involving PLX-200. The update was categorized as "Designation Grant," with the company reporting: "Polaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II)."

What conditions do Polaryx Therapeutics' current drugs treat?

Currently, Polaryx Therapeutics has one therapy (PLX-200) targeting the following condition: For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis.